MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents

Journal of Clinical Oncology

Volumn 34, Issue 28, 2016, Pages 3451-3459

  Suzuki, Kyogo ^a   Okuno, Yusuke ^a,b   Kawashima, Nozomu ^a   Muramatsu, Hideki ^a   Okuno, Tatsuya ^a   Wang, Xinan ^a   Kataoka, Shinsuke ^a   Sekiya, Yuko ^a   Hamada, Motoharu ^a   Murakami, Norihiro ^a   Kojima, Daiei ^a   Narita, Kotaro ^c   Narita, Atsushi ^a   Sakaguchi, Hirotoshi ^c   Sakaguchi, Kimiyoshi ^d   Yoshida, Nao ^c   Nishio, Nobuhiro ^a,b   Hama, Asahito ^a   Takahashi, Yoshiyuki ^a   Kudo, Kazuko ^e   Kato, Koji ^c   Kojima, Seiji ^a   more..

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE SODIUM PHOSPHATE; GENOMIC DNA; HISTONE DEACETYLASE 9; QUISINOSTAT; RNA; VORINOSTAT; BCL9 PROTEIN, HUMAN; DEXAMETHASONE; HDAC9 PROTEIN, HUMAN; HISTONE DEACETYLASE; HYDROXAMIC ACID; MEF2D PROTEIN, HUMAN; MYOCYTE ENHANCER FACTOR 2; ONCOPROTEIN; REPRESSOR PROTEIN; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; BCL9 GENE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER RISK; CHILD; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; FUSION GENE; GENE EXPRESSION; GENE FUSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; IN VITRO STUDY; INFANT; MAJOR CLINICAL STUDY; MALE; MEF2D GENE; MOLECULARLY TARGETED THERAPY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RNA SEQUENCE; BIOSYNTHESIS; BLOOD; DRUG SCREENING; GENETICS; HEK293 CELL LINE; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEQUENCE ANALYSIS; TUMOR CELL CULTURE; TUMOR CELL LINE;

ADOLESCENT; BORTEZOMIB; CELL LINE, TUMOR; CHILD; DEXAMETHASONE; DRUG SCREENING ASSAYS, ANTITUMOR; HEK293 CELLS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INFANT; MEF2 TRANSCRIPTION FACTORS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REPRESSOR PROTEINS; RNA, NEOPLASM; SEQUENCE ANALYSIS, RNA; TUMOR CELLS, CULTURED;

EID: 84990046288     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.66.5547     Document Type: Article

References (35)

1. Pui CH, Mullighan CG, Evans WE, et al: Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood 120:1165-1174, 2012
2. Schultz KR, Bowman WP, Aledo A, et al: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 27:5175-5181, 2009
3. Roberts KG, Li Y, Payne-Turner D, et al: Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371:1005-1015, 2014
4. Hunger SP, Lu X, Devidas M, et al: Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children's oncology group. J Clin Oncol 30:1663-1669, 2012
5. Suzuki N, Yumura-Yagi K, Yoshida M, et al: Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol. Pediatr Blood Cancer 54:71-78, 2010
6. Asai D, Imamura T, Suenobu S, et al: IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. Cancer Med 2:412-419, 2013
7. Kim D, Salzberg SL: TopHat-Fusion: An algorithm for discovery of novel fusion transcripts. Genome Biol 12:R72, 2011
8. Trapnell C, Williams BA, Pertea G, et al: Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28:511-515, 2010
9. Love MI, Huber W, Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550, 2014
10. Koboldt DC, Zhang Q, Larson DE, et al: Var-Scan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22:568-576, 2012
11. de Hoon MJ, Imoto S, Nolan J, et al: Open source clustering software. Bioinformatics 20:1453-1454, 2004
12. Saldanha AJ: Java Treeview-extensible visualization of microarray data. Bioinformatics 20:3246-3248, 2004
13. Faham M, Zheng J, Moorhead M, et al: Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120:5173-5180, 2012
14. van Dongen JJ, Langerak AW, Brüggemann M, et al: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317, 2003
15. Brochet X, Lefranc MP, Giudicelli V: IMGT/V-QUEST: The highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 36:W503-W508, 2008
16. Giudicelli V, Brochet X, Lefranc MP: IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc 2011:695-715, 2011
17. Kanda Y: Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452-458, 2013
18. Moreno DA, Scrideli CA, Cortez MA, et al: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 150:665-673, 2010
19. Milde T, Oehme I, Korshunov A, et al: HDAC5 and HDAC9 in medulloblastoma: Novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 16:3240-3252, 2010
20. Dus-Szachniewicz K, Wozniak M, Nelke K, et al: Protein tyrosine phosphatase receptor R and Z1 expression as independent prognostic indicators in oral squamous cell carcinoma. Head Neck 37:1816-1822, 2015
21. Ma Y, Ye F, Xie X, et al: Significance of PTPRZ1 and CIN85 expression in cervical carcinoma. Arch Gynecol Obstet 284:699-704, 2011
22. Waters KM, Sontag RL, Weber TJ: Hepatic leukemia factor promotes resistance to cell death: Implications for therapeutics and chronotherapy. Toxicol Appl Pharmacol 268:141-148, 2013
23. Zhang C, Richon V, Ni X, et al: Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045-1052, 2005
24. Arts J, King P, Mariën A, et al: JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 15:6841-6851, 2009
25. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
26. Roberts KG, Morin RD, Zhang J, et al: Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22:153-166, 2012
27. Molkentin JD, Olson EN: Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad Sci USA 93:9366-9373, 1996
28. Shin HH, Seoh JY, Chung HY, et al: Requirement of MEF2D in the induced differentiation of HL60 promyeloid cells. Mol Immunol 36:1209-1214, 1999
29. Suzuki T, Shen H, Akagi K, et al: New genes involved in cancer identified byretroviral tagging. Nat Genet 32:166-174, 2002
30. Willis TG, Zalcberg IR, Coignet LJ, et al: Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 91:1873-1881, 1998
31. Takada K, Zhu D, Bird GH, et al: Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 4:148ra117, 2012
32. Mani M, Carrasco DE, Zhang Y, et al: BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 69:7577-7586, 2009
33. Prima V, Gore L, Caires A, et al: Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia. Leukemia 19:806-813, 2005
34. Yuki Y, Imoto I, Imaizumi M, et al: Identification of a novel fusion gene in a pre-B acute lymphoblastic leukemia with t(1;19)(q23;p13). Cancer Sci 95:503-507, 2004
35. Prima V, Hunger SP: Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia. Leukemia 21:2470-2475, 2007